Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 3 9Phase 1/2 5

Status

Unknown 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Breast 1

Conditions

Solid Tumor 1Small Cell Lung Carcinoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Disease Progression 1Breast Neoplasms 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × famitinib × Clear all
NCT05176080 2024-12-17

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Henan Cancer Hospital

Phase 1/2 Terminated
46 enrolled
Breast

Breast Neoplasms

NCT06332950 2024-03-27

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

Shanghai Chest Hospital

Phase 1/2 Not yet recruiting
80 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT04679038 2022-01-26

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
222 enrolled
Other solid neoplasm

Solid Tumor

NCT05020925 2021-08-25

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
30 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04044378 2020-05-19

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Peking University People's Hospital

Phase 1/2 Withdrawn

Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡